Evidence map›Paper›PMID 41006227›Full record

ArticleNature communications2025

Effects of individual variation and seasonal vaccination on disease risks.

William S Hart, Jina Amin, Hyeongki Park, Kosaku Kitagawa, Yong Dam Jeong, Alexander R Kaye, Shingo Iwami, Robin N Thompson

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William S HartWolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK. william.hart@maths.ox.ac.uk.ORCID http://orcid.org/0000-0002-2504-6860
Jina AminWolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0009-2007-6655
Hyeongki ParkSchool of Biomedical Convergence Engineering, Pusan National University, Busan, South Korea.
Kosaku Kitagawainterdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Yong Dam Jeonginterdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-3970-7690
Alexander R KayeMathematics Institute, University of Warwick, Coventry, UK.
Shingo Iwamiinterdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1780-350X
Robin N ThompsonWolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-8545-5212

Funding

RCUK | Engineering and Physical Sciences Research Council (EPSRC) Vacation InternshipRoyal Society IES-R3-193037
6 · The paper itself

Abstract

Estimates of the risk of a large outbreak resulting from pathogen introduction into a population are valuable for planning interventions. Two key factors affecting outbreak risks are variation in transmission between individuals (e.g., superspreading individuals) and change over time (e.g., through seasonality or changing population immunity due to vaccination). Here, we develop an outbreak risk estimation framework that accounts for both features simultaneously. To demonstrate the real-world application of our framework, we consider the design of annual COVID-19 booster vaccination campaigns, using a multi-scale approach incorporating an individual-level model of vaccine-induced antibody dynamics. Near the start of annual vaccine distribution, when population immunity is low, a high outbreak risk is possible; this can be mitigated by distributing vaccines over a longer period. We show that longer distribution periods are particularly beneficial if vaccine coverage and/or effectiveness is high, and if seasonality in transmission is limited.

Indexed as

COVID-19COVID-19 VaccinesSeasonsVaccinationDisease OutbreaksHumansImmunization, SecondarySARS-CoV-2COVID-19 Vaccines

Identifiers

PMID41006227
PMCPMC12475144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.